These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22006179)

  • 1. A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer.
    Moulder S; Gladish G; Ensor J; Gonzalez-Angulo AM; Cristofanilli M; Murray JL; Booser D; Giordano SH; Brewster A; Moore J; Rivera E; Hortobagyi GN; Tran HT
    Cancer; 2012 May; 118(9):2378-84. PubMed ID: 22006179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 and pharmacokinetic study of everolimus, a mammalian target of rapamycin inhibitor, in combination with docetaxel for recurrent/refractory nonsmall cell lung cancer.
    Ramalingam SS; Harvey RD; Saba N; Owonikoko TK; Kauh J; Shin DM; Sun SY; Strychor S; Tighiouart M; Egorin MJ; Fu H; Khuri FR
    Cancer; 2010 Aug; 116(16):3903-9. PubMed ID: 20564143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer.
    Fury MG; Sherman E; Ho AL; Xiao H; Tsai F; Nwankwo O; Sima C; Heguy A; Katabi N; Haque S; Pfister DG
    Cancer; 2013 May; 119(10):1823-31. PubMed ID: 23408298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors.
    Amin M; Gao F; Terrero G; Picus J; Wang-Gillam A; Suresh R; Ma C; Tan B; Baggstrom M; Naughton MJ; Trull L; Belanger S; Fracasso PM; Lockhart AC
    Am J Clin Oncol; 2021 Sep; 44(9):443-448. PubMed ID: 34310349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M; Yamamoto N; Makino Y; Ando-Makihara R; Ohe Y; Takano M; Hayashi Y
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):713-21. PubMed ID: 26233803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.
    Zhang X; Zhang S; Liu Y; Liu J; Ma Y; Zhu Y; Zhang J
    Eur J Cancer; 2012 Jul; 48(10):1581-92. PubMed ID: 22420943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factor.
    Pavlick AC; Chodkiewicz C; Liebes L; Hamilton A; Wasserheit C; Hochster H; Speyer J; Phillips Z; Downey A; Sorich J; Muggia F
    Anticancer Drugs; 2004 Feb; 15(2):119-25. PubMed ID: 15075667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies.
    Awada A; Zhang S; Gil T; de Valeriola D; Lalami Y; De Porre P; Piccart-Gebhart MJ
    Curr Med Res Opin; 2007 May; 23(5):991-1003. PubMed ID: 17519066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
    Kosmas C; Tsavaris N; Mylonakis N; Tsakonas G; Gassiamis A; Skopelitis H; Polyzos A; Malamos N; Karabelis A
    J Chemother; 2007 Jun; 19(3):322-31. PubMed ID: 17594929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer.
    Jerusalem G; Fasolo A; Dieras V; Cardoso F; Bergh J; Vittori L; Zhang Y; Massacesi C; Sahmoud T; Gianni L
    Breast Cancer Res Treat; 2011 Jan; 125(2):447-55. PubMed ID: 21107682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab.
    Andre F; Campone M; O'Regan R; Manlius C; Massacesi C; Sahmoud T; Mukhopadhyay P; Soria JC; Naughton M; Hurvitz SA
    J Clin Oncol; 2010 Dec; 28(34):5110-5. PubMed ID: 20975068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of bi-weekly docetaxel for recurrent or advanced gastric cancer patients whose disease progressed by prior chemotherapy.
    Kimura Y; Yano H; Taniguchi H; Iwazawa T; Danno K; Kagara N; Kanoh T; Ohnishi T; Tono T; Nakano Y; Monden T; Imaoka S
    Jpn J Clin Oncol; 2011 Jun; 41(6):747-51. PubMed ID: 21498408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].
    Li JL; Zhang XR; Liu JW; Chen ZY; Lin YC; Wang YD; Chen Q; Nan KJ; Song SP; Han FC; Zhu YZ; Li LY; Zheng YH; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2006 Apr; 28(4):309-12. PubMed ID: 16875636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer.
    Singh J; Novik Y; Stein S; Volm M; Meyers M; Smith J; Omene C; Speyer J; Schneider R; Jhaveri K; Formenti S; Kyriakou V; Joseph B; Goldberg JD; Li X; Adams S; Tiersten A
    Breast Cancer Res; 2014 Mar; 16(2):R32. PubMed ID: 24684785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck.
    Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR
    Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.
    Lim T; Lee J; Lee DJ; Lee HY; Han B; Baek KK; Ahn HK; Lee SJ; Park SH; Park JO; Park YS; Lim HY; Kim KM; Kang WK
    Cancer Chemother Pharmacol; 2011 Jul; 68(1):255-62. PubMed ID: 21526353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer.
    Bayet-Robert M; Kwiatkowski F; Leheurteur M; Gachon F; Planchat E; Abrial C; Mouret-Reynier MA; Durando X; Barthomeuf C; Chollet P
    Cancer Biol Ther; 2010 Jan; 9(1):8-14. PubMed ID: 19901561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
    Deenen MJ; Klümpen HJ; Richel DJ; Sparidans RW; Weterman MJ; Beijnen JH; Schellens JH; Wilmink JW
    Invest New Drugs; 2012 Aug; 30(4):1557-65. PubMed ID: 21809026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I-II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer.
    Kosmas C; Tsavaris N; Malamos N; Stavroyianni N; Gregoriou A; Rokana S; Polyzos A
    Br J Cancer; 2003 Apr; 88(8):1168-74. PubMed ID: 12698179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.